Insider

AbbVie Inc.

ABBV Health Care · 6 analyses · 3 expectations tracked

AbbVie reported $17.4B in revenue (+10.3% YoY), compared with a +7.2% median across covered Health Care peers. Of 3 tracked management expectations, 2 were consistent with later reports and 0 were contradicted. 1 insider sale recorded. Next scheduled event: Dividend on February 16, 2027.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

Deals & ownership

AbbVie executives conducted stock transactions in mid-November

AbbVie Inc. executives Jeffrey R. Stewart and Azita Saleki-Gerhardt conducted a series of company stock transactions between November 9 and November 16, 2026. The executives exercised stock options and filed notices of proposed sales as part of managing their personal equity holdings.

· AbbVie Inc.
Daily briefing

Corporate updates and financial results

Companies report on shareholder meeting results, leadership changes, technology updates, and share buyback programs. Below is a summary of key recent events.

What changed

AbbVie reports revenue growth and raises annual guidance

AbbVie reported $17.404 billion in net revenue for the third quarter of 2026, a 10.3% increase year-over-year. Diluted earnings per share (EPS) was $2.37 on a GAAP basis, and $3.82 on an adjusted basis. The company raised its full-year adjusted EPS guidance to $13.95–$13.99.

· AbbVie Inc.
Show all articles (6)

Upcoming events

As announced by the companies, read by code from their press releases, 8-Ks and official feeds; each date links its announcement. Companies can change dates. Dividends: common shares only; under T+1 settlement the ex-dividend date is normally the record date. Corporate calendar →

Company history

October 2026

AbbVie Inc.: 12 recorded developments from 6 official sources in 2026-10.

  • 2026-09-30: Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity Index. Source
  • 2026-10-05: There can be no assurance that our final results will not differ from these preliminary estimates. Source
  • 2026-10-05: While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Source
  • 2026-10-05: Adjusted diluted earnings per share guidance for 2026 previously announced on July 31, 2026 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2026. Source
  • 2026-10-05: Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2026 are expected to include acquired IPR&D and milestones expense of $216 million on a pre-tax basis, representing an unfavorable impact of $0.11 to both GAAP diluted earnings per share and adjusted non-GAAP Source
  • 2026-10-05: Results for the quarter ended September 30, 2026 have not been finalized and are subject to our financial statement closing procedures. Source
  • 2026-10-11: New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints Source
  • 2026-10-13: AbbVie presented new Phase 3 AFFIRM data showing clinical and endoscopic outcomes with subcutaneous SKYRIZI in patients with moderately to severely active Crohn's disease. Source
  • 2026-10-15: On October 14, 2026, AbbVie Inc. expanded its Board of Directors from twelve to thirteen directors and appointed Dr. John M. Carethers as a Class II director. Source
  • 2026-10-15: Dr. John M. Carethers was appointed to the Public Policy and Sustainability Committee of AbbVie. Source
  • 2026-10-15: The Board affirmatively determined that Dr. John M. Carethers is an independent director under NYSE standards and AbbVie's guidelines. Source
  • 2026-10-30: AbbVie Inc. issued a press release on October 30, 2026, announcing financial results for the third quarter ended September 30, 2026. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed November 3, 2026. SEC

LatestEarlierChange
Revenue quarter$17.4B$15.8B+10.3%
Operating income quarter$6.3B$1.9B+229.1%
Net income quarter$4.2B$186M+2,167.7%
Diluted EPS quarter$2.37$0.10+2,270.0%
Dividends per share quarter$1.73$1.64+5.5%
Operating cash flow year to date$14.9B$13.8B+7.7%
Cash and cash equivalents balance$10.8B$5.2B+106.0%

Next results expected around February 2, 2027 (estimate: the quarter ending about December 30, 2026 plus the 34 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

15.1Q4 '24-9.9%13.3Q1 '2528%15.4Q2 '2531.7%15.8Q3 '2512.1%16.6Q4 '2527.3%15Q1 '2626.6%17Q2 '2637.9%17.4Q3 '2636%
Bottom row: operating margin (operating income divided by revenue). Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
AbbVie Inc. ABBV$17.4B+10.3%36.0%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

How expectations played out

2 of 3 expectations checked against later reports

  • 2 confirmed

Mostly AI assessments, provisional; an editor's decision replaces them. Not a rating of the shares.

Checked against later reports

  • AbbVie raised its adjusted diluted EPS guidance for the full year 2026 to $13.95 - $13.99.

    Said October 30, 2026 · Period named: full year 2026 · Source · Our article

    AI assessment, provisional later reports are consistent with it (as of November 16, 2026) · Later article

  • Raised 2026 adjusted diluted EPS guidance range to $13.95 - $13.99.

    Said October 30, 2026 · Period named: 2026 · Source · Our article

    AI assessment, provisional later reports are consistent with it (as of November 16, 2026) · Later article

Open

  • Regulatory submissions for lutikizumab in HS are expected.

    Said October 30, 2026 · Period named: second half of 2027 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
November 2, 2026Director or officer departure or appointment (8-K item 5.02)8-K
October 15, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 16, 2026Azita Saleki-GerhardtPlanned sale13,481—$4,024,851SEC
November 9, 2026Jeffrey R StewartPlanned sale40,619—$11,925,848SEC
November 9, 2026Jeffrey Ryan StewartSale40,619$293.60$11,925,738SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock148,974,939$38,970,354,223-0.3%Q3 2026
State Street82,815,387$21,663,677,085+0.3%Q3 2026
Geode Capital Management47,503,777$12,404,019,552+1.1%Q3 2026
Capital Research Global Investors31,115,872$8,139,628,876+3.4%Q3 2026
Norges Bank (Norway's sovereign fund)25,554,538$6,430,543,942—Q2 2026
Fidelity (FMR)20,186,300$5,280,534,136-2.8%Q3 2026
Wellington Management10,705,904$2,800,557,428+111.8%Q3 2026
Citadel Advisors609,263$159,377,108-80.8%Q3 2026
D. E. Shaw & Co.591,521$154,735,978-71.9%Q3 2026
Millennium Management144,668$37,843,702-90.5%Q3 2026
Two Sigma Investments94,792$24,796,639-52.2%Q3 2026
T. Rowe Price14,759,347$3,860,898+0.1%Q3 2026
Bridgewater Associates11,775$2,963,061-61.2%Q2 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.